Source: Annual Congress 2006 - Miscellaneous respiratory infections II
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Y. V. Popovych, T. O. Pertseva, O. V. Bratus (Dnipropetrovs‘k, Ukraine). The etiology and antimicrobial drugs resistance of microorganisms in patients with community-acquired pneumonia. Eur Respir J 2006; 28: Suppl. 50, 131

Member's Comments

No comment yet.

Related content which might interest you: Previous antibacterial therapy and drug-resistance among pathogens in ICU patients with nosocomial pneumonia Source: Eur Respir J 2001; 18: Suppl. 33, 405s Year: 2001 Ventilator-associated pneumonia due to colistin susceptible-only microorganisms Source: Eur Respir J 2007; 30: 307-313 Year: 2007 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 The etiological agents of community-acquired pneumonia in our hospital Source: Eur Respir J 2006; 28: Suppl. 50, 735s Year: 2006 Antibiotic treatment for nosocomial pneumonia Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=211 Year: 2004 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Potential antibiotic resistant pathogens in community-acquired pneumonia: playing it safe is anything but Source: Eur Respir J, 54 (1) 1900870; 10.1183/13993003.00870-2019 Year: 2019 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Antibiotic resistance and nosocomial pneumonia Source: Eur Respir J 2005; 26: Suppl. 49, 641s Year: 2005 Impact of reducing antibiotic treatment on inflammation among patients with community-acquired pneumonia. Source: International Congress 2019 – Prognosis in bacterial and viral pneumonia Year: 2019 Aerosolized colistin in critically ill patients for the treatment of ventilator-associated pneumonia, due to multidrug-resistant gram-negative bacteria Source: Eur Respir J 2006; 28: Suppl. 50, 786s Year: 2006 Importance of appropriate initial antibiotic therapy and de-escalation in the treatment of nosocomial pneumonia Source: Eur Respir Rev 2007; 16: 33-39 Year: 2007 Aspiration risks factors, microbiology and empiric antibiotics for patients hospitalized with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Infective agents and their antibiotic susceptibility in patients with respiratory infections Source: Eur Respir J 2005; 26: Suppl. 49, 639s Year: 2005 Diagnosis and treatment of nosocomial pneumonia in ALI/ARDS patients Source: Eur Respir J 2003; 22: 77S-83S Year: 2003 Bacterial agents of community-acquired lower respiratory tract infections: observational study on antimicrobial drugs susceptibility Source: Eur Respir J 2002; 20: Suppl. 38, 421s Year: 2002 Hospital-acquired pneumonia: microbiological data and potential adequacy of antimicrobial regimens Source: Eur Respir J 2002; 20: 432-439 Year: 2002 Community-acquired pneumonia in Europe: causative pathogens and resistance patterns Source: Eur Respir J 2002; 20: 20S-27S Year: 2002 Macrolides and lower respiratory tract infections Source: ISSN=1025-448x, ISBN=1-904097-32-4, page=78 Year: 2004